Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating ...

NanoCas, an ultracompact nuclease, enables efficient muscle editing in NHPs using a single AAV - advancing gene editing for hard-to-target tissues.

A £1.65 million treatment has been approved for use for some NHS patients, offering some with an inherited blood disorder ...

Base editing utilizes enzymes to modify single amino acids at the most foundational unit of DNA, called a base.

The UK has approximately 17,500 individuals living with sickle cell disease, a condition particularly prevalent amongst those ...

Financial writer discusses MGX's gene editing technology, cash runway, and lack of clinical data for potential future ...

The therapy involves taking stem cells out of a patient's bone marrow and editing a gene in the cells in a laboratory and ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modelling and interrogating human disease.

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating human disease.

It’s a new way to create “bi-paternal” mice that can survive to adulthood—but human applications are still a long way off.

Australian researchers have successfully introduced an improved version of Cas12a gene-editing enzyme in mice.